Metabolism of cholecystokinin-33 in vivo: effect of L-364,718, a CCK receptor antagonist. 1994

R Hosotani, and R Doi, and Y Gu, and M Wada, and K Inoue, and N Fujii, and P L Rayford, and M Imamura
First Department of Surgery, Kyoto University, Japan.

Metabolism of cholecystokinin (CCK) and the effect of L-364,718, a specific CCK-A receptor antagonist, on the metabolism of CCK were examined in dogs. In conscious dogs, 45 min intravenous infusion of synthetic human CCK-33 (100 pmol/Kg/hr) caused an integrated CCK response over 90 min of 675 +/- 51 pmol-90 min/L, and the plasma CCK levels declined promptly with a t1/2 of 2.2 +/- 0.3 min after cessation. Organ extraction of CCK-33 by the kidney, mesenteric organs, and liver was examined in anesthetized dogs. From the gradients of the plasma levels between afferent and efferent vessels for each organ after bolus injection of CCK-33 (50 pmol/Kg), renal extraction ratio was 0.30 +/- 0.04, and mesenteric extraction ratio was 0.19 +/- 0.04. Hepatic extraction was not detected. T1/2 and extraction ratios were not affected by the preinjection of L-364,718 (20 nmol/Kg). The results indicate in dogs that exogenously administered CCK-33 is degraded by the mesenteric organs as well as the kidney but not by the liver, and that receptor-mediated mechanisms are not involved in these degradation pathways of CCK.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008643 Mesentery A layer of the peritoneum which attaches the abdominal viscera to the ABDOMINAL WALL and conveys their blood vessels and nerves. Mesenteries
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D011949 Receptors, Cholecystokinin Cell surface proteins that bind cholecystokinin (CCK) with high affinity and trigger intracellular changes influencing the behavior of cells. Cholecystokinin receptors are activated by GASTRIN as well as by CCK-4; CCK-8; and CCK-33. Activation of these receptors evokes secretion of AMYLASE by pancreatic acinar cells, acid and PEPSIN by stomach mucosal cells, and contraction of the PYLORUS and GALLBLADDER. The role of the widespread CCK receptors in the central nervous system is not well understood. CCK Receptors,Caerulein Receptors,Cholecystokinin Octapeptide Receptors,Cholecystokinin Receptors,Pancreozymin Receptors,Receptors, CCK,Receptors, Caerulein,Receptors, Pancreozymin,Receptors, Sincalide,Sincalide Receptors,CCK Receptor,CCK-4 Receptors,CCK-8 Receptors,Cholecystokinin Receptor,Receptors, CCK-4,Receptors, CCK-8,Receptors, Cholecystokinin Octapeptide,CCK 4 Receptors,CCK 8 Receptors,Octapeptide Receptors, Cholecystokinin,Receptor, CCK,Receptor, Cholecystokinin,Receptors, CCK 4,Receptors, CCK 8
D002766 Cholecystokinin A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety. Pancreozymin,CCK-33,Cholecystokinin 33,Uropancreozymin
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Hosotani, and R Doi, and Y Gu, and M Wada, and K Inoue, and N Fujii, and P L Rayford, and M Imamura
October 1997, Pancreas,
R Hosotani, and R Doi, and Y Gu, and M Wada, and K Inoue, and N Fujii, and P L Rayford, and M Imamura
May 1993, Pancreas,
R Hosotani, and R Doi, and Y Gu, and M Wada, and K Inoue, and N Fujii, and P L Rayford, and M Imamura
April 1987, The Journal of pharmacology and experimental therapeutics,
R Hosotani, and R Doi, and Y Gu, and M Wada, and K Inoue, and N Fujii, and P L Rayford, and M Imamura
May 2001, American journal of physiology. Regulatory, integrative and comparative physiology,
R Hosotani, and R Doi, and Y Gu, and M Wada, and K Inoue, and N Fujii, and P L Rayford, and M Imamura
March 1994, Pancreas,
R Hosotani, and R Doi, and Y Gu, and M Wada, and K Inoue, and N Fujii, and P L Rayford, and M Imamura
December 1996, International journal of pancreatology : official journal of the International Association of Pancreatology,
R Hosotani, and R Doi, and Y Gu, and M Wada, and K Inoue, and N Fujii, and P L Rayford, and M Imamura
January 1989, Gastroenterology,
R Hosotani, and R Doi, and Y Gu, and M Wada, and K Inoue, and N Fujii, and P L Rayford, and M Imamura
January 1989, Gut,
R Hosotani, and R Doi, and Y Gu, and M Wada, and K Inoue, and N Fujii, and P L Rayford, and M Imamura
October 1989, European journal of clinical investigation,
R Hosotani, and R Doi, and Y Gu, and M Wada, and K Inoue, and N Fujii, and P L Rayford, and M Imamura
March 1988, European journal of pharmacology,
Copied contents to your clipboard!